Welcome to our dedicated page for International Flavors & Fragrances news (Ticker: IFF), a resource for investors and traders seeking the latest updates and insights on International Flavors & Fragrances stock.
International Flavors & Fragrances Inc. reports developments across flavors, fragrances, food ingredients, health and biosciences for customers in food, beverage, personal care, home care, pet health and related markets. News frequently covers ingredient innovation, application labs and natural-extraction capabilities, including vanilla work in Madagascar and LMR Naturals in perfumery, cosmetics and flavors.
Company updates also address probiotics and bioscience products such as HOWARU Pet and PureStrong, nutrition claims tied to soy protein, quarterly earnings releases, dividends, and other capital or financial disclosures.
IFF (NYSE:IFF) will release its fourth quarter and full year 2021 earnings on February 9, 2022, after market close. A live webcast for discussion of results and outlook will follow on February 10, 2022, at 9:00 a.m. ET. Investors can access the webcast and presentation on the Company’s website. IFF is a leader in food, beverage, scent, and biosciences, offering innovative solutions globally.
On February 14, 2022, IFF appointed Frank Clyburn as CEO, succeeding Andreas Fibig. Clyburn, previously President of Human Health at Merck, boasts extensive experience in global business operations and leadership. His tenure at Merck involved full P&L responsibility for a $48 billion business and significant achievements in oncology. The transition comes alongside the separation of the Chairman and CEO roles, with Dale Morrison becoming non-executive Chairman. This change aims to enhance IFF’s strategic execution, driven by Clyburn's expertise in customer relations and operational discipline.
IFF (NYSE: IFF) and SleepScore Labs have unveiled a new scent solution aimed at enhancing sleep quality, following their 2020 partnership. This innovative scent, developed through comprehensive studies, demonstrated objective sleep improvements, including faster sleep onset and increased duration. The solution will be showcased at CES 2022 in Las Vegas. With 70% of the developed world affected by sleep issues, IFF and SleepScore's collaboration utilizes data-driven approaches to offer scientifically validated sleep solutions.
Summary not available.
IFF (NYSE: IFF) announced a quarterly cash dividend of $0.79 per share, payable on January 7, 2022, to shareholders on record as of December 28, 2021. This declaration reflects the company's commitment to returning value to its shareholders while continuing to innovate in the food, beverage, scent, and biosciences sectors. As an industry leader, IFF combines science and creativity to deliver high-quality solutions.
Cabot Corporation (NYSE: CBT) has signed a Memorandum of Understanding (MOU) with IFF Health and Biosciences to develop and commercialize sustainable reinforcing additives for rubber products. This collaboration aims to reduce greenhouse gas emissions and increase renewable bio-based content in rubber applications. Utilizing IFF’s Nuvolve™ engineered polysaccharide, developed from European sugar beets, Cabot will lead the project, integrating it with its reinforcing carbons. This partnership aligns with Cabot's commitment to sustainability and innovation in the rubber industry.
IFF announced a substantial investment of $87 million to expand its flavors manufacturing facility in Karawang, Indonesia. This facility, the largest in Greater Asia, enhances IFF's capabilities to meet the growing demand for flavor technology. The 12,800m2 state-of-the-art facility focuses on efficiency, sustainability, and quality control, contributing to IFF's strategy of targeting emerging markets in Asia. With this investment, IFF aims to capitalize on the significant growth potential in the region, expected to account for half of global consumption growth in the next decade.
International Flavors & Fragrances (IFF) reported strong financial results for Q3 2021, achieving double-digit sales growth for the second consecutive quarter. Reported net sales reached $3.1 billion, a 142% increase year-over-year, driven by the merger with Nutrition & Biosciences. Adjusted operating EBITDA rose 135% to $648 million. However, macro supply chain challenges have impacted profitability margins, with an updated guidance for 2021 sales of approximately $11.55 billion and adjusted operating EBITDA margin at 21.0%.
IFF (NYSE:IFF) will release its third quarter earnings on November 8, 2021, after market close. A live webcast to discuss results will occur on November 9, 2021, at 10:00 a.m. ET. Investors can access the webcast and slides on the Company's website, with a recorded version available for later viewing. IFF focuses on creating essential solutions in food, beverage, scent, health, and biosciences, aiming to enhance human experiences and sustainability.
Andreas Fibig, CEO and Chairman of IFF, will retire after a decade with the company. The Board is currently evaluating successors and expects to announce a new CEO by early 2022. Fibig noted IFF's strong sales growth and successful integration of Nutrition & Biosciences, expressing pride in transforming the company into a sustainability leader. His retirement marks a significant transition, but he will assist in the handover process. IFF aims to continue driving long-term value for stakeholders while navigating the ongoing challenges of the market.